An accountant by profession, Laurence Tiennot-Herment found herself launched into the world of disease prevention and the various associations working in this field in 1989 as a result of her son’s illness. Having previously worked for the Telethon and AFM in Seine-Maritime, her native region, she joined AFM Board of Directors in 1997. She was elected first Secretary and then Vice-President, before taking the position of President of AFM in 2003. Since 2005, she has also been President of the Institut de Myologie, and of Genethon since 2009. In addition to her responsibilities within AFM and its “operational branches”, Laurence Tiennot-Herment is Director of the public interest group Genopole, and of the Imagine Foundation, as well as sitting on the management committee of the scientific interest group Institut des Maladies Rares.
|Chief Executive Officer
Frédéric Revah, Ph.D. email@example.com
As the Chief Executive Officer of Genethon, Frédéric Revah has more than twenty years’ experience in the pharmaceutical and biotech industries as well as in academic research. Immediately prior to joining Genethon in January 2010, he had been Chief Executive Officer at Sepal Pharma (oncology), before which he was CEREP’s Vice-President of Drug Discovery and Scientific Director from 1999-2007, as well as being Chief Executive Officer of its oncology arm. He was also head of the CNS Gene Therapy Department and the Neurochemistry Department at Rhône-Poulenc Rorer (now Sanofi-Aventis) from 1992 to 1998.
Frédéric Revah started his career as an associate staff researcher at the Institut Pasteur (from 1990 to 1992). He obtained his doctorate at the Institut Pasteur / Université de Paris V in 1991, and graduated from the Ecole Polytechnique engineering school in 1985.
Fulvio Mavilio, Ph.D. firstname.lastname@example.org
He was Director of Discovery of Molmed SpA (2002-2005), founder and Chief Scientific Officer of Genera SpA (1999-2002), and co-Director of the San Raffaele-Telethon Institute of Gene Therapy in Milan, Italy (1995 to 2002). Member of the European Molecular Biology Association (EMBO), Chairman of the Educational Committee of the American Society of Gene Therapy (ASGT), and member of the Editorial Board of many international journals in the fields of genetics, molecular biology and gene therapy. He graduated in Biology at the University of Rome in 1976, obtained a Ph.D. in Medical Genetics at the School of Medicine of the same University in 1979, and trained as a visiting scientist at the Wistar Institute in Philadelphia (PA, USA) from 1985 to 1989. An expert and a pioneer in the fields of gene therapy and stem cell research, and published over 140 articles in major international journals. He is also Professor of Molecular Biology at University of Modena and Reggio Emilia (Modena, Italy).
|Director of Clinical Development
Géraldine Honnet, M.D. email@example.com
Before joining Genethon, Géraldine served as Head of Clinical Development in Infectious Diseases at Transgene, International Project Manager at Janssen-Cilag and Medical Director at Parexel International.
|Director of Partnerships & Business Development
Alexandre Lemoalle firstname.lastname@example.org
Alexandre has more than twenty years experience in the pharma industry. Before joining Genethon he had different functions in Finance within Sanofi and then as General Manager of subsidiaries and VP Mergers & Acquisitions for the group Sanofi. He then accompanied biotechs in their development and advised some Funds in their investments in Health sector. Alexandre is graduated from l’Institut Supérieur de Gestion (ISG).